UroGen Pharma Ltd. — Director's Dealing 2026

Feb 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2026-01-31

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-31	Ordinary Shares	M	3333	—	Acquired	145692	Direct
2026-01-31	Ordinary Shares	M	6666	—	Acquired	152358	Direct
2026-01-31	Ordinary Shares	M	3334	—	Acquired	142359	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-31	Restricted Stock Units	$	M	3333	Disposed		Ordinary Shares (3333)	Direct
2026-01-31	Restricted Stock Units	$	M	6666	Disposed		Ordinary Shares (6666)	Direct
2026-01-31	Restricted Stock Units	$	M	3334	Disposed		Ordinary Shares (3334)	Direct
2026-01-31	Restricted Stock Units	$	A	20000	Acquired		Ordinary Shares (20000)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: The reporting person was granted RSUs on January 31, 2025 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026.

F3: The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.

F4: The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.

F5: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.